Clinical trials: Cephalalgia
Migraine
Study to Test a Marketed Drug in the Treatment of Menstrual Migraine (0462-072)
The purpose of this study is to test the effectiveness of a marketed drug in the treatment of a menstrual migraine attack.
- Trial name
- NCT00111722
- Testing
- MK0462, rizatriptan benzoate / Duration of Treatment -1day
- Volunteers
- 393 people
- Sponsor
- Organon and Co
Migraine, Headache
Efficacy and Safety of a Fixed-dose Combination of Naratriptan and Naproxen in Acute Treatment of Migraine.
The purpose of this study is to determine whether a fixed-dose combination of naratriptan 2,5 mg + naproxen 500 mg is effective and safe compared each monotherapy for the acute treatment of migraine.
- Trial name
- Copérnico (NCT01726920)
- Testing
- naratriptan + naproxen, naratriptan, naproxen
- Sponsor
- Ache Laboratorios Farmaceuticos S.A.
Migraine
A Multicenter Study to Evaluate the Efficacy of a 91-Day Extended Cycle Oral Contraceptive for Menstrually-Related Migraine Headaches
This study is being conducted to evaluate the efficacy of a 91-day extended cycle oral contraceptive compared to placebo for decreasing the frequency and severity of menstrually-related migraine headaches.
- Trial name
- NCT00781456
- Testing
- 91-day Levonorgestrel Oral Contraceptive
- Where
- 22 sites in United States
- Volunteers
- 109 people
- Sponsor
- Duramed Research
Migraine
Retrospective Study on the Use of CEFALY® Device During Migraine Attacks
This is an Internet survey to collect data on the use of the Cefaly device to treat migraine attacks in regular Cefaly users.
- Trial name
- NCT02616978
- Volunteers
- 807 people
- Sponsor
- Cefaly Technology
Migraine
Bioavailability Study to Compare OPTINOSE SUMATRIPTAN With IMITREX® in Healthy Subjects
The purpose of this study is: To compare the single-dose pharmacokinetics (PK) of intranasal administration of 20 mg OPTINOSE SUMATRIPTAN with 20 mg IMITREX® (sumatriptan) Nasal Spray, 100 mg IMITREX® (sumatriptan) Oral Tablet…
- Trial name
- NCT01507610
- Testing
- Sumatriptan
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Optinose US Inc.
Migraine, Migraine Disorders
Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA)
This study was designed to determine efficacy of TREXIMET (sumatriptan/naproxen sodium), formerly known as TREXIMA compared to placebo for the treatment of a menstrual migraine.
- Trial name
- NCT00329355
- Testing
- sumatriptan succinate/naproxen sodium
- Where
- 35 sites in United States
- Volunteers
- 351 people
- Sponsor
- GlaxoSmithKline
Migraine Disorders
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache
Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS in patients with a single acute migraine attack with or without aura
- Trial name
- NCT02198339
- Testing
- BIBN 4096 BS
- Volunteers
- 126 people
- Sponsor
- Boehringer Ingelheim
Migraine Headaches
The Safety Of Combo Formulation In The Treatment Of Multiple Episodes Of Acute Migraine Over 12 Months
The objective of this study is to assess the safety of a single-tablet dose of Combo Formulation for the treatment of moderate to severe migraines
- Trial name
- NCT00442221
- Testing
- Sumatriptan and Naproxen sodium
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- POZEN
Migraine
A Phase III Trial of e-TNS for the Acute Treatment of Migraine
The main objective of this study is to have Phase III evidences of the efficacy of the Cefaly® Abortive Program device used at home for 2 hours to treat a migraine attack.
- Trial name
- TEAM (NCT03465904)
- Testing
- Verum Cefaly® Abortive Program device
- Where
- 10 sites in United States
- Volunteers
- 607 people
- Sponsor
- Cefaly Technology
Migraine Disorders
A Multicenter Assessment of ALD403 in Chronic Migraine
The purpose of this study is to assess ALD403 in the prevention of migraine headache in chronic migraineurs.
- Trial name
- NCT02275117
- Testing
- ALD403
- Where
- 92 sites in United States, Australia and 2 more
- Volunteers
- 665 people
- Sponsor
- Alder Biopharmaceuticals, Inc.
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine
A Study of Lasmiditan (LY573144) Over Four Migraine Attacks
The reason for this study is to see how effective and safe the study drug known as lasmiditan is in the acute treatment of 4 migraine attacks with or without aura.
- Trial name
- NCT03670810
- Testing
- Lasmiditan
- Where
- 141 sites in United States, Austria and 15 more
- Volunteers
- 1,633 people
- Sponsor
- Eli Lilly and Company
Migraine
A Study of LY3451838 in Participants With Migraine
The reason for this study is to see if the study drug LY3451838 is safe and effective in participants who have migraine that have not responded to other preventive treatments.
- Trial name
- NCT04498910
- Testing
- LY3451838
- Where
- 9 sites in United States
- Volunteers
- 38 people
- Sponsor
- Eli Lilly and Company
Migraine, Acute Treatment of Migraine
Treatment Patterns Among US Veterans Using Remote Electrical Neuromodulation (REN) for Migraine Treatment
Among US veterans, migraine is a prevalent and disabling neurological disorder, creating a clinical need for effective treatment options.
- Trial name
- NCT07336420
- Testing
- Nerivio REN device
- Where
- United States
- Volunteers
- 466 people
- Sponsor
- Theranica
Migraine
Efficacy of AJOVY (Fremanezumab-vfrm) on Interictal Migraine Related Burden
This study is being conducted to evaluate the efficacy and safety of AJOVY (fremanezumab-vfrm) on interictal migraine related burden in adults.
- Trial name
- NCT04461795
- Testing
- Fremanezumab-Vfrm 225 MG/1.5 ML Subcutaneous Solution [AJOVY]
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- David True
Migraine
Efficacy and Safety of Subcutaneous Administration of TEV-48125 for the Preventive Treatment of Chronic Migraine
To evaluate the efficacy and safety of subcutaneous (SC) administration of TEV-48125 [monthly TEV-48125 225 mg (loading dose only: 675 mg) and TEV-48125 675 mg once over a period of 3 months] compared with placebo for preventive…
- Trial name
- NCT03303079
- Testing
- TEV-48125
- Where
- Japan
- Volunteers
- 571 people
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
Migraine, Common Migraine
A Study of the Efficacy and Safety of Topiramate in the Prevention of Migraine
The purpose of this study is to evaluate the safety and efficacy of three doses of topiramate (50 milligrams[mg], 100mg, and 200mg per day) compared with placebo in the prevention of migraine.
- Conditions
- Migraine, Common Migraine, Classic Migraine, Headache
- Trial name
- NCT00231595
- Testing
- topiramate
- Volunteers
- 768 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Episodic Migraine
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have…
- Trial name
- NCT03927144
- Testing
- AMG334, Oral Prophylactic
- Where
- 112 sites in United States, Argentina and 16 more
- Volunteers
- 621 people
- Sponsor
- Amgen
Migraine
Fremanezumab Managed Access Program for Pediatric Patients
This is a Managed Access Program (MAP) based on a licensed physician's unsolicited request on a compassionate basis. Specifically, this MAP is for male and female pediatric patients 6 to 17 years with a diagnosis of either…
- Trial name
- NCT03539393
- Testing
- Fremanezumab
- Sponsor
- Teva Branded Pharmaceutical Products R&D LLC
Influenza
Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults
The purpose of this study is to determine if favipiravir is effective in reducing the time to resolution of influenza symptoms.
- Trial name
- NCT02008344
- Testing
- favipiravir
- Where
- 247 sites in United States, Argentina and 9 more
- Volunteers
- 1,161 people
- Sponsor
- MDVI, LLC